Search results
Showing 1251 to 1300 of 2048 results for work
This guideline covers identifying and treating primary hypertension (high blood pressure) in people aged 18 and over, including people with type 2 diabetes. It aims to reduce the risk of cardiovascular problems such as heart attacks and strokes by helping healthcare professionals to diagnose hypertension accurately and treat it effectively.
This quality standard covers care for adults before, during and after primary elective hip, knee or shoulder joint replacement. It describes high-quality care in priority areas for improvement. It does not cover joint replacement as treatment for primary or secondary cancer affecting the bones.
View quality statements for QS206Show all sections
Sections for QS206
- Quality statements
- Quality statement 1: Preoperative rehabilitation advice for hip and knee replacement
- Statement 2: Choice between partial and total knee replacement
- Statement 3: Tranexamic acid during hip and knee replacement
- Quality statement 4: Preventing implant selection errors
- Statement 5: Postoperative rehabilitation
- Update information
- About this quality standard
This quality standard covers diagnosing, monitoring and managing asthma in children, young people and adults. It describes high-quality care in priority areas for improvement.
View quality statements for QS25Show all sections
Sections for QS25
- Quality statements
- Quality statement 1: Objective tests to support diagnosis
- Quality statement 2: Documented personalised action plan
- Quality statement 3: Monitoring asthma control
- Quality statement 4: Follow-up by general practice after emergency care
- Quality statement 5 (developmental): Suspected severe asthma
- Update information
- About this quality standard
This quality standard covers the identification and management of familial and genetic risk and the recognition and management of ovarian, fallopian tube and primary peritoneal cancer or borderline ovarian cancer in women, trans men and non-binary people aged 18 and over with female reproductive organs (ovaries, fallopian tubes or a uterus). It describes high-quality care in priority areas for improvement.
View quality statements for QS18Show all sections
Sections for QS18
- Quality statements
- Quality statement 1: Discussion about risk-reducing surgery
- Quality statement 2: CA125 blood test – age-specific thresholds
- Quality statement 3: Panel germline genetic testing for non-mucinous high-grade epithelial ovarian cancer
- Quality statement 4: Tumour genetic testing for stage 3 or 4 non-mucinous high-grade epithelial ovarian cancer
- Quality statement 5: Treatment of high-risk stage 1 or stage 2 to 4 ovarian cancer
- Update information
- About this quality standard
Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [TSID12203]
In development Reference number: GID-TA11781 Expected publication date: TBC
Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]
In development Reference number: GID-TA11272 Expected publication date: TBC
In development Reference number: GID-TA11709 Expected publication date: TBC
In development Reference number: GID-TA10882 Expected publication date: TBC
In development Reference number: GID-TA11372 Expected publication date: TBC
Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer [ID6277]
Discontinued Reference number: GID-TA11302
In development Reference number: GID-TA10747 Expected publication date: TBC
Discontinued Reference number: GID-TA11318
Discontinued Reference number: GID-TA11343
In development Reference number: GID-TA11365 Expected publication date: TBC
Evidence-based recommendations on lumasiran (Oxlumo) for primary hyperoxaluria type 1 in people of all ages.
Discontinued Reference number: GID-TAG423
Discontinued Reference number: GID-TA10018
Nilotinib for the first line treatment of chronic myeloid leukaemia [ID79]
Discontinued Reference number: GID-TAG408
Avelumab for treating non-small-cell lung cancer after platinum-based chemotherapy [ID1146]
Discontinued Reference number: GID-TA10341
Discontinued Reference number: GID-TA10365
Discontinued Reference number: GID-TA10019
Discontinued Reference number: GID-TAG407
Discontinued Reference number: GID-TA10353
Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer [ID1335]
Discontinued Reference number: GID-TA10315
Discontinued Reference number: GID-TA10425
Atezolizumab for treating metastatic colorectal cancer after 2 therapies [ID1298]
Discontinued Reference number: GID-TA10228
Nivolumab for small-cell lung cancer after platinum-based chemotherapy [ID1126]
Discontinued Reference number: GID-TA10158
Autologous haematopoietic stem cell transplantation for treating multiple sclerosis [ID1111]
Discontinued Reference number: GID-TA10306
Nivolumab for untreated advanced hepatocellular carcinoma [ID1248]
Discontinued Reference number: GID-TA10221
In development Reference number: GID-TA11273 Expected publication date: TBC
This guideline sets out an antimicrobial prescribing strategy for adults, young people and children aged 72 hours and over with impetigo. It aims to optimise antibiotic use and reduce antibiotic resistance.
Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing (NG114)
This guideline sets out an antimicrobial prescribing strategy for acute exacerbations of chronic obstructive pulmonary disease (COPD). It aims to optimise antibiotic use and reduce antibiotic resistance.
This guideline sets out an antimicrobial prescribing strategy for acute sore throat. It aims to limit antibiotic use and reduce antimicrobial resistance. Acute sore throat is often caused by a virus, lasts for about a week, and most people get better without antibiotics. Withholding antibiotics rarely leads to complications.
Nivolumab with radiation therapy for previously untreated glioblastoma multiforme [ID1562]
Discontinued Reference number: GID-TA10443
In development Reference number: GID-TA11301 Expected publication date: TBC
Discontinued Reference number: GID-TAG400
Etirinotecan pegol for treating breast cancer with brain metastases [ID881]
Discontinued Reference number: GID-TA10066
Discontinued Reference number: GID-TA10543
Discontinued Reference number: GID-TA10499
Mogamulizumab for previously treated T-cell leukaemia-lymphoma [ID1390]
Discontinued Reference number: GID-TA10464
Discontinued Reference number: GID-TA10502
In development Reference number: GID-TA11449 Expected publication date: TBC
Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer [TSID10701]
In development Reference number: GID-TA11157 Expected publication date: TBC
In development Reference number: GID-TA11367 Expected publication date: TBC
In development Reference number: GID-TA11589 Expected publication date: TBC
In development Reference number: GID-TA11475 Expected publication date: TBC
Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170]
Discontinued Reference number: GID-TA10254
Masitinib for treating amyotrophic lateral sclerosis [ID967]
Discontinued Reference number: GID-TA10157
In development Reference number: GID-TA11844 Expected publication date: TBC